Literature DB >> 34316007

Harnessing murine models of Crohn's disease ileitis to advance concepts of pathophysiology and treatment.

Lida Iliopoulou1, George Kollias2,3.   

Abstract

Crohn's disease (CD) and ulcerative colitis (UC) are both characterized by chronic inflammation and severe dysfunction of the gastrointestinal tract. These two forms of inflammatory bowel disease (IBD) represent distinct clinical disorders with diverse driving mechanisms; however, this divergence is not reflected in currently approved therapeutics that commonly target general proinflammatory pathways. A compelling need therefore remains to understand factors that differentiate the topology and the distinct clinical manifestations of CD versus UC, in order to develop more effective and specialized therapies. Animal models provide valuable platforms for studying IBD heterogeneity and deciphering disease-specific mechanisms. Both the established and the newly developed ileitis mouse models are characterized by various disease initiating mechanisms and diverse phenotypic outcomes that reflect the complexity of human CD-ileitis. Microbial dysbiosis, destruction of epithelial barrier integrity, immune cell deregulation, as well as the recently described genome instability and stromal cell activation have all been proposed as the triggering factors for the development of ileitis-associated pathology. In this review, we aim to critically evaluate the mechanistic underpinnings of murine models of CD-ileitis, discuss their phenotypic similarities to human disease, and envisage their further exploitation for the development of novel targeted and personalized therapeutics.
© 2021. The Author(s), under exclusive licence to Society for Mucosal Immunology.

Entities:  

Mesh:

Year:  2021        PMID: 34316007     DOI: 10.1038/s41385-021-00433-3

Source DB:  PubMed          Journal:  Mucosal Immunol        ISSN: 1933-0219            Impact factor:   7.313


  135 in total

Review 1.  Clinical aspects and pathophysiology of inflammatory bowel disease.

Authors:  Barbara A Hendrickson; Ranjana Gokhale; Judy H Cho
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

Review 2.  Diagnostic problems and advances in inflammatory bowel disease.

Authors:  Robert Odze
Journal:  Mod Pathol       Date:  2003-04       Impact factor: 7.842

Review 3.  The global burden of IBD: from 2015 to 2025.

Authors:  Gilaad G Kaplan
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-09-01       Impact factor: 46.802

Review 4.  Current and emerging therapeutic targets for IBD.

Authors:  Markus F Neurath
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-02-01       Impact factor: 46.802

Review 5.  British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.

Authors:  Christopher Andrew Lamb; Nicholas A Kennedy; Tim Raine; Philip Anthony Hendy; Philip J Smith; Jimmy K Limdi; Bu'Hussain Hayee; Miranda C E Lomer; Gareth C Parkes; Christian Selinger; Kevin J Barrett; R Justin Davies; Cathy Bennett; Stuart Gittens; Malcolm G Dunlop; Omar Faiz; Aileen Fraser; Vikki Garrick; Paul D Johnston; Miles Parkes; Jeremy Sanderson; Helen Terry; Daniel R Gaya; Tariq H Iqbal; Stuart A Taylor; Melissa Smith; Matthew Brookes; Richard Hansen; A Barney Hawthorne
Journal:  Gut       Date:  2019-09-27       Impact factor: 23.059

Review 6.  Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice.

Authors:  Javier P Gisbert; María Chaparro
Journal:  J Crohns Colitis       Date:  2020-06-19       Impact factor: 9.071

Review 7.  Animal models of inflammatory bowel diseases: illuminating the pathogenesis of colitis, ileitis and cancer.

Authors:  Markus F Neurath
Journal:  Dig Dis       Date:  2012-10-11       Impact factor: 2.404

8.  Inflammatory bowel disease-like enteritis and caecitis in a senescence accelerated mouse P1/Yit strain.

Authors:  S Matsumoto; Y Okabe; H Setoyama; K Takayama; J Ohtsuka; H Funahashi; A Imaoka; Y Okada; Y Umesaki
Journal:  Gut       Date:  1998-07       Impact factor: 23.059

9.  Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin.

Authors:  M L Hermiston; J I Gordon
Journal:  Science       Date:  1995-11-17       Impact factor: 47.728

10.  Pediatric Crohn disease patients exhibit specific ileal transcriptome and microbiome signature.

Authors:  Yael Haberman; Timothy L Tickle; Phillip J Dexheimer; Mi-Ok Kim; Dora Tang; Rebekah Karns; Robert N Baldassano; Joshua D Noe; Joel Rosh; James Markowitz; Melvin B Heyman; Anne M Griffiths; Wallace V Crandall; David R Mack; Susan S Baker; Curtis Huttenhower; David J Keljo; Jeffrey S Hyams; Subra Kugathasan; Thomas D Walters; Bruce Aronow; Ramnik J Xavier; Dirk Gevers; Lee A Denson
Journal:  J Clin Invest       Date:  2014-07-08       Impact factor: 14.808

View more
  1 in total

1.  Ileitis-associated tertiary lymphoid organs arise at lymphatic valves and impede mesenteric lymph flow in response to tumor necrosis factor.

Authors:  Rafael S Czepielewski; Emma C Erlich; Emily J Onufer; Shannon Young; Brian T Saunders; Yong-Hyun Han; Mary Wohltmann; Peter L Wang; Ki-Wook Kim; Shashi Kumar; Chyi-Song Hsieh; Joshua P Scallan; Ying Yang; Bernd H Zinselmeyer; Michael J Davis; Gwendalyn J Randolph
Journal:  Immunity       Date:  2021-11-16       Impact factor: 31.745

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.